857283-98-8

Basic information

• Product Name: BENZO[B]FURAN-3-YLACETYL CHLORIDE
• Synonyms: BENZO[B]FURAN-3-YLACETYL CHLORIDE;Benzo[b]furan-3-ylacetyl chloride 97%;3-[(Chlorocarbonyl)methyl]-1-benzofuran, (1-Benzofuran-3-yl)acetyl chloride, 2-(1-Benzofuran-3-yl)ethanoyl chloride;3-Benzofuranacetyl chloride
• CAS NO: 857283-98-8
• Molecular Formula: C₁₀H₇ClO₂
• Molecular Weight: 194.61
• Product Categories: Furan&Benzofuran
• Mol File: 857283-98-8.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 289.6 °C at 760 mmHg
• Flash Point: 128.9 °C
• Appearance: /
• Density: 1.317 g/cm³
• Vapor Pressure: 0.00218mmHg at 25°C
• Refractive Index: 1.604
• CAS DataBase Reference: BENZO[B]FURAN-3-YLACETYL CHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: BENZO[B]FURAN-3-YLACETYL CHLORIDE(857283-98-8)
• EPA Substance Registry System: BENZO[B]FURAN-3-YLACETYL CHLORIDE(857283-98-8)

Safety Data

• Hazard Codes: C
• Statements: 14-29-34
• Safety Statements: 8-23-29-30-36/37/39-45
• RIDADR: 3265
• Hazardous Substances Data: 857283-98-8(Hazardous Substances Data)

Usage

Description

BENZO[B]FURAN-3-YLACETYL CHLORIDE is a chemical compound with the molecular formula C11H9ClO2. It is a derivative of benzo[b]furan, a heterocyclic compound containing a furan ring fused to a benzene ring. The acetyl chloride functional group consists of a carbonyl group attached to a chlorine atom, making it a reactive compound commonly used in organic synthesis.

Uses

Used in Pharmaceutical Industry:
BENZO[B]FURAN-3-YLACETYL CHLORIDE is used as a versatile intermediate for the synthesis of various pharmaceuticals. Its reactive acetyl chloride group allows for the formation of a wide range of organic compounds, making it a valuable building block in the development of new drugs.
Used in Agrochemical Industry:
BENZO[B]FURAN-3-YLACETYL CHLORIDE is also used as a key intermediate in the production of agrochemicals. Its ability to form various organic compounds makes it useful in the synthesis of pesticides, herbicides, and other agricultural chemicals.
Used in Organic Synthesis:
BENZO[B]FURAN-3-YLACETYL CHLORIDE is used as a reactive intermediate in organic synthesis for the production of a variety of organic compounds. Its acetyl chloride functional group allows for the formation of esters, amides, and other organic compounds, making it a valuable tool in the synthesis of complex molecules.
It is important to handle BENZO[B]FURAN-3-YLACETYL CHLORIDE with care due to its corrosive and irritating nature. Proper safety measures should be taken to minimize exposure and potential hazards.

InChI:InChI=1/C10H7ClO2/c11-10(12)5-7-6-13-9-4-2-1-3-8(7)9/h1-4,6H,5H2

Upstream product

• 64175-51-5 2-(3-benzofuranyl)acetic acid 
• 7169-34-8 3-oxo-2,3-dihydrobenzo[b]furan 
• 82156-58-9 benzofuran-3-yl-acetic acid ethyl ester 

Downstream Products

• 1070313-28-8 N-(2-(benzofuran-3-yl)acetyl)-5-bromo-N-(2-methylbenzyl)furan-2-carboxamide 

Relevant articles and documents

FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[H] quinoline-4-carboxylic acid (PSI-697): Identification of a clinical candidate from the quinoline salicylic acid series of P-selectin antagonists

P-selectin-PSGL-1 interaction causes rolling of leukocytes on the endothelial cell surface, which subsequently leads to firm adherence and leukocyte transmigration through the vessel wall into the surrounding tissues. P-selectin is upregulated on the surface of both platelets and endothelium in a variety of atherosclerosis-associated conditions. Consequently, inhibition of this interaction by means of a small molecule P-selectin antagonist is an attractive strategy for the treatment of atherosclerosis. High-throughput screening and subsequent analoging had led to the identification of compound 1 as the lead candidate. Herein, we report the continuation of this work and the discovery of a second-generation series, the tetrahydrobenzoquinoline salicylic acids. These compounds have improved pharmacokinetic properties, and a number of them have shown oral efficacy in mouse and rat models of atherogenesis and vascular injury. The lead 31 (PSI-697), is currently in clinical development for the treatment of atherothrombotic vascular events.